HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

mitratapide

Anti-Obesity Agents; structure in first source

Also Known As:

R 103757; R103757

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - mitratapide: 2
  - Piperazines: 26
    - mitratapide: 2

Experts

1.	Bautista-Castaño, Inmaculada: 1 article (09/2014)
2.	Carretón, Elena: 1 article (09/2014)
3.	Juste, M Candelaria: 1 article (09/2014)
4.	Montoya-Alonso, José Alberto: 1 article (09/2014)
5.	Peña, Cristina: 1 article (09/2014)
6.	Suarez, Lourdes: 1 article (09/2014)
7.	De Bock, Manuelle: 1 article (12/2009)
8.	Dobenecker, Britta: 1 article (12/2009)
9.	Engelen, Marc: 1 article (12/2009)
10.	Goossens, Lieve: 1 article (12/2009)

Related Diseases

1.	Weight Loss (Weight Reduction) 12/01/2009 - "The objective of this study was to confirm that weight loss after treatment with mitratapide (Yarvitan®) is loss of adipose tissue. "
2.	Obesity 09/01/2014 - "On the other hand, mitratapide seems to present certain beneficial effects on pathologies associated with obesity, these being mainly related to blood pressure, lipids and hepatic parameters. "
3.	Insulin Resistance 12/01/2009 - "The results also suggest that losing weight with mitratapide might help to reverse insulin resistance."
4.	Body Weight (Weight, Body) 09/01/2014 - "Effects of low-fat high-fibre diet and mitratapide on body weight reduction, blood pressure and metabolic parameters in obese dogs."

Related Drugs and Biologics

1.	Lipids

Related Therapies and Procedures

1.	Aftercare (After-Treatment)